Dual inhibition of MEK1/2 and EGFR synergistically induces caspase-3-dependent apoptosis in EGFR inhibitor-resistant lung cancer cells via BIM upregulation

Growth-Inhibitory and Antiangiogenic Activity of the MEK Inhibitor PD0325901 in Malignant Melanoma with or without BRAF Mutations

(2015) Ludovica Ciuffreda et al.   NEOPLASIA

Selumetinib: a promising pharmacologic approach forKRAS-mutant advanced non-small-cell lung cancer

(2013) Giulio Metro et al.   Future Oncology

Tumour cell responses to MEK1/2 inhibitors: acquired resistance and pathway remodelling

(2012) Annette S. Little et al.   BIOCHEMICAL SOCIETY TRANSACTIONS

Intrinsic resistance to selumetinib, a selective inhibitor of MEK1/2, by cAMP-dependent protein kinase A activation in human lung and colorectal cancer cells

(2012) T Troiani et al.   BRITISH JOURNAL OF CANCER

Gefitinib-Resistance Is Related to BIM Expression in Non-Small Cell Lung Cancer Cell Lines

(2012) Heyan Li et al.   CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS

Primary and Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer: An Update

(2012) Ayodele Ayoola et al.   CANCER INVESTIGATION

Phase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With MetastaticBRAF-Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF Inhibitor

(2012) Kevin B. Kim et al.   JOURNAL OF CLINICAL ONCOLOGY

Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study

(2012) Pasi A Jänne et al.   LANCET ONCOLOGY

Global cancer statistics

(2011) Ahmedin Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Personalized medicine in lung cancer: what we need to know

(2011) Tony S. K. Mok   Nature Reviews Clinical Oncology

Differential Sensitivity of ERBB2 Kinase Domain Mutations towards Lapatinib

(2011) Rama Krishna Kancha et al.   PLoS One

MEK1/2 Inhibitors AS703026 and AZD6244 May Be Potential Therapies forKRASMutated Colorectal Cancer That Is Resistant to EGFR Monoclonal Antibody Therapy

(2010) Juyong Yoon et al.   CANCER RESEARCH

Randomized Phase II Multicenter Trial of Two Schedules of Lapatinib as First- or Second-Line Monotherapy in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer

(2010) H. J. Ross et al.   CLINICAL CANCER RESEARCH

A Phase II, Open-Label, Randomized Study to Assess the Efficacy and Safety of AZD6244 (ARRY-142886) Versus Pemetrexed in Patients with Non-small Cell Lung Cancer Who Have Failed One or Two Prior Chemotherapeutic Regimens

(2010) John D. Hainsworth et al.   Journal of Thoracic Oncology

KRASmutant lung cancer cells are differentially responsive to MEK inhibitor due to AKT or STAT3 activation: Implication for combinatorial approach

(2010) Young-Kwang Yoon et al.   MOLECULAR CARCINOGENESIS

Apoptosis and autophagy: BIM as a mediator of tumour cell death in response to oncogene-targeted therapeutics

(2009) Annette S. Gillings et al.   FEBS Journal

KRAS/BRAF mutation status and ERK1/2 activation as biomarkers for MEK1/2 inhibitor therapy in colorectal cancer

(2009) J. J. Yeh et al.   MOLECULAR CANCER THERAPEUTICS

Tumour cell survival signalling by the ERK1/2 pathway

(2008) K Balmanno et al.   CELL DEATH AND DIFFERENTIATION

Advances in Targeting the Ras/Raf/MEK/Erk Mitogen-Activated Protein Kinase Cascade with MEK Inhibitors for Cancer Therapy

(2008) B. B. Friday et al.   CLINICAL CANCER RESEARCH

Lapatinib: A dual inhibitor of human epidermal growth factor receptor tyrosine kinases

(2008) P MEDINA et al.   CLINICAL THERAPEUTICS

Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic

(2008) Mark S. Cragg et al.   JOURNAL OF CLINICAL INVESTIGATION